NCT02571530: Super-selective Intra-arterial Cerebral Infusion of Trastuzumab for the Treatment of Cerebral Metastases of HER2/Neu Positive Breast Cancer

NCT02571530
Breast Cancer Type: HER2+
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: Brain
Additional Notes: 
Exclusions: Patients with leptomeningeal dissemination of brain metastases
https://ClinicalTrials.gov/show/NCT02571530

Comments are closed.

Up ↑